Not All HAs are Created Equal
DUROLANE’s key advantages matter for your knee OA patients
DUROLANE, a single-injection hyaluronic acid (HA) treatment, can significantly improve the quality of life for knee osteoarthritis (OA) patients as soon as 2 weeks after injection.20
DUROLANE has the highest reported molecular weight of any HA—1015kDa.‡43,46
Here are more of DUROLANE’s key advantages:
DUROLANE is a non-animal, stabilized HA that is cross-linked and entangled to create an HA with a long residence time.10
DUROLANE has:
- A half-life of 30 days (approximately 4 weeks) in the knee joint in a single-injection treatment regimen35
- The longest reported half-life of any HA32-35
DUROLANE is the only FDA-approved single-injection HA for the treatment of knee OA pain proven to be clinically equivalent to a five-injection therapy.13,24
In a Level 1 study:11
- DUROLANE was proven to be non-inferior to a steroid at 6 weeks.||
- Researchers found a significant reduction in WOMAC pain from baseline with DUROLANE vs a steroid at week 26 [p=0.034]¶
Find a sales representative or contact us with your questions about DUROLANE
‡Based on theoretical calculations
§Animal performance may not be predictive of performance in humans.
||Methylprednisolone acetate (MPA)
¶The primary outcome was the WOMAC pain responder rate, defined as at least 40% relative improvement and 5-point absolute improvement from baseline values at 12 weeks.